Lyon

• FAPI-PET value for the initial screening of pancreatic and biliary cancers (FAPDIG Study) Recruiting
  2024-517270-23-00 4 2026-03-05 Cholangiocarcinoma
• An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with sele … Recruiting
  2024-519788-16-00 4 2026-03-05 Adult patients with histologically/cytologically confirmed progressive
• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin … Recruiting
  2023-506291-28-00 5 2026-03-02 Patient with locally advanced/metastatic, MSI-H/dMMR gastric cancer
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w … Recruiting
  2025-522139-33-00 7 2026-02-10 Advanced or metastatic solid tumours
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part … Recruiting
  2025-522151-26-00 5 2026-02-06 Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Recruiting
  2025-521909-40-00 4 2026-01-28 Patients with metastatic or locally advanced HER2-low triple-negative
• Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors Recruiting
  2025-521828-30-00 9 2026-01-27 Advanced Solid Tumors
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A Phase 1/2 First-Time-in-Human study of GSK5458514 administered alone or in combination with other anti-cancer agents in participants with … Recruiting
  2025-521581-10-00 7 2026-01-16 Neoplasms, Prostate
• A study to find a suitable dose of ASP5834 in adults with solid tumors Recruiting
  2025-522082-29-00 1 2026-01-16 Locally advanced (unresectable) or metastatic solid tumor malignancies
• NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l … Recruiting
  2025-522127-95-00 4 2026-01-12 NEOREM: Localized solid malignancies that are eligible to receive neo-
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 11 2025-12-18 Neovascular age-related macular degeneration
• A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced S … Recruiting
  2025-521407-52-00 1 2025-12-16 Advanced Solid Tumors
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma

Showing 169–192 of 882 trials